The place of ezetimibe in clinical practice

Hospital Medicine

Volumn 64, Issue 8, 2003, Pages 473-478

  Weston, Clive ^a  

^a SINGLETON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN; AZETIDINE DERIVATIVE; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ABSORPTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; ENTEROHEPATIC CIRCULATION; HUMAN; LIVER FUNCTION; MEDICAL PRACTICE; MONOTHERAPY; MUSCLE DISEASE; NONHUMAN; REVIEW; RHABDOMYOLYSIS; TOXICITY; UNITED KINGDOM; DRUG COMBINATION; DRUG INTERACTION; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; METABOLISM;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II;

EID: 0141594739     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2003.64.8.2262     Document Type: Review

References (47)

1. Assmann G, Cullen P, Schulte H (1998) The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 19(suppl A): A2-A11
2. Ballantyne CM (2002) Ezetimibe: efficacy and safety in clinical trials. Eur Heart J Supplements 4(suppl J): J9-J18
3. Ballantyne CM, Houri J, Notarbartolo A et al (2003) Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomised, double-blind trial. Circulation 107: 2409-15
4. Broom I, Hughes E, Dodson P et al (2002) The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. Br J Cardiol 9: 460-8
5. Brown AS, Bakker-Arkema RG, Yellen L et al (1998) Treating patients with documented Atherosclerosis to National Cholesterol Education Program-recommended low-density -lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 32: 665-72
6. Buchwald H, Varco RL, Boen JR et al (1998) Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Arch Intern Med 158: 1253-61
7. Canner PL, Berge GK, Wender NK et al (1986) Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 18: 1245-55
8. Castelli WP, Garrison RJ, Wilson PW et al (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256: 2835-8
9. Davidson MH (2002) Combination therapy for dyslipidemia; safety and regulatory considerations. Am J Cardiol 90: 50K-60K
10. Davis HR, Compton DS, Hoos L, Tetzloff G (2001) Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice. Arterioscler Thromb Vasc Biol 21: 2032-8
11. de Lorgeril M, Renaud S, Mamelle N et al (1994) Mediterranean alpha-linoleic acid-rich diet in secondary prevention of coronary heart disease. Lancet 343: 1454-9
12. Department of Health (2000) National Service Framework for Coronary Artery Disease. Department of Health, London
13. Dobs AS, Guyton JR, McClusky D et al (2003) Coadministration of ezetimibe with simvastatin. J Am Coll Caediol 41(suppl A): 227A
14. Dujovne CA, Ettinger MP, McNeer JF et al (2002a) Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90: 1092-7
15. Dujovne C, Held J, Lipka L al al (2002b) Does cholesterol and/or fat intake effect plasma lipid efficacy of ezetimibe? J Am Coll Cardiol 39(suppl A): 227A
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285: 2486-97
17. Farnier M (2002) Ezetimibe in hypercholesterolaemia. Int J Clin Pract 56: 611-14
18. Feher MD (2003) Lipid lowering to delay progression of coronary artery disease. Heart 89: 451-8
19. Fodor G, Frolich JJ, Genest Jr JJG et al (2000) Recommendations for the management and treatment of dyslipidemia. Can Med Assoc J 162: 1441-7
20. Gagne C, Gaudet D, Bruckert E et al (2002a) Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105: 2469-75
21. Gagne C, Bays HE, Weiss SR et al (2002b) Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90: 1084-91
22. Gould AL, Rossouw JE, Santello NC et al (1998) Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97: 946-52
23. Gylling H, Rajaratnam R, Miettinen TA (1997) Reduction in serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine. Circulation 96: 4226-31
24. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised, placebo-controlled trial. Lancet 360: 7-22
25. Hippisley-Cox J, Cater R, Pringle M, Coupland C (2003) Cross sectional survey of effectiveness of lipid lowering drugs in reducing cholesterol concentration in patients in 17 general practices. Br Med J 326: 689-94
26. Kastelein JJP, van Dam MJ (2001) A new role for combination therapy in lipid management. Br J Cardiol 8: 639-53
27. Kerzner B, Corbelli J, Sharp S et al (2003) Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 91: 418-24
28. Knopp RH (1999) Drug treatment of lipid disorders. N Engl J Med 341: 498-511
29. Knopp RH, Walden CE, Retzlaff BM et al (1997) Long-term cholesterol-lowering effects of four fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study. JAMA 278: 1509-15
30. Kosoglou T, Guillaume M, Sun S et al (2001) Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe. (abstract) Atherosclerosis 2(suppl): 38
31. Kosoglou T, Meyer I, Veltri EP et al (2002) Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 54: 309-19
32. Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251: 351-64
33. Melani L, Mills R, Hassman D et al (2003) Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolaemia: a prospective, randomised, double-blind trial. Eur Heart J 24: 717-28
34. Miettinen TA (2001) Cholesterol absorption inhibition: A strategy for cholesterol-lowering therapy. Int J Clin Pract 55: 710-16
35. Miettinen TA, Gylling H (1999) Regulation of cholesterol metabolism by dietary plant sterols. Curr Opin Lipidol 10: 9-14
36. Minhas R (2003) Current progress in lipid therapy. Br J Cardiol 10: 59-68
37. Mitchell JC, Logan GM, Stone BG et al (1991) Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans. J Lipid Res 32: 71-8
38. Primatesta P, Poulter N (2000) Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. Br Med J 321: 1322-5
39. Ridker PM, Rifai N, Clearfield M et al (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959-65
40. Rubins HB, Robins SJ (2000) Conclusions from the VA-HIT study. Am J Cardiol 86: 543-4
41. Rubinstein A, Weintraub M (1995) Escape phenomenon of low-density lipoprotein cholesterol during lovastatin treatment. Am J Cardiol 76: 184-6
42. Sacks FM, Pfeffer MA, Moye EA (1996) The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The CARE study. N Engl J Med 335: 1001-9
43. Sagar P, Melani L, Lipka L et al (2003) Ezetimibe coadministered with low dose statins in primary hypercholesterolemia: lipid profiles comparable to high-dose statin monotherapy. J Am Coll Cardiol 41(suppl A): 255A
44. Stein EA, Stender S, Mata P et al (2003) Ezetimibe coadministered with atorvastatin compared to atorvastatin alone in the attainment of low-density lipoprotein goals among high-risk patients with hypercholesterolemia. J Am Coll Cardiol 41(suppl A): 255A
45. Sudhop T, Lutjohann D, Kodal A et al (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106: 1943-8
46. Wood D, Durrington P, Poulter N et al (1998) Joint Recommendations on prevention of coronary heart disease in clinical practice. Heart 80(suppl 2): 1-29
47. Xydakis AM, Ballantyne CM (2002) Combination therapy for combined dyslipidemia. Am J Cardiol 90: 21K-29K